# Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center

> **NIH NIH R50** · RESEARCH INST OF FOX CHASE CAN CTR · 2020 · $128,392

## Abstract

Project Summary
I am the Manager of the High Throughput Screening Facility (HTSF) at the NCI-designated comprehensive
cancer center Fox Chase Cancer Center (FCCC). The HTSF provides screening platforms and specialized
instrumentation for increased experimental throughput. In particular, the HTSF allows investigators to utilize
RNAi and compound libraries, and the specialized instrumentation required for large scale screening with these
resources. I have been the Manager of the HTSF since its inception, and have guided the establishment and
maintenance of every aspect of the facility. I managed the acquisition of a suite of HTS equipment and libraries,
established all the standard operating procedures (SOPs) and created a working pipeline from assay
development to statistical hit-picking for investigators. After the establishment of the HTSF under my
management, on its first review by the NCI in 2010 as a proposed facility for addition to the Cancer Center
Support Grant (CCSG), it was rated as “Outstanding.” Overall, the vitality of the resource I have created for
molecular screening is evidenced by forty-four publications that have utilized the HTSF between the years 2007-
2015. Within the most recent CCSG review period (2011-2014), there was a three-fold increase in the total
number of publications over the first CCSG review period. During this time period, there was an average of over
one thousand individual reservations for equipment use per annum. These data indicate that the resources I
have established and continue to develop are robust and a pivotal scientific asset for the laboratories at FCCC.
As technologies and research directions evolve, I have surveyed the faculty to identify new technology platforms
for the HTSF, and I have led the preparation of two S10 shared instrumentation grants two successful S10
applications allowing the purchase of the Guava EasyCyte benchtop FACS, and a Luminex 100/200, multiplexing
biomarker analyzer. The acquisition of this new technology platform will complement the resources available to
screeners, but crucially allow the HTSF to serve investigators utilizing patient samples and animal models. My
efforts supporting and implementing the technologies provided in the HTSF is crucial to their continued
excellence and availability.

## Key facts

- **NIH application ID:** 10005259
- **Project number:** 5R50CA211479-04
- **Recipient organization:** RESEARCH INST OF FOX CHASE CAN CTR
- **Principal Investigator:** MARGRET B EINARSON
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $128,392
- **Award type:** 5
- **Project period:** 2019-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10005259

## Citation

> US National Institutes of Health, RePORTER application 10005259, Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center (5R50CA211479-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10005259. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*